Lianghao Mao

No.438, Jiefang Road
Zhenjiang, 212000, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

BAF complex-independent gene activation by SS18::SSX.

BAF complex-independent gene activation by SS18::SSX.

Journal: bioRxiv : the preprint server for biology
Published: February 09, 2026

cIAP1 inhibitor of apoptosis is a tumor suppressor in Ewing sarcoma.

cIAP1 inhibitor of apoptosis is a tumor suppressor in Ewing sarcoma.

Journal: Cancer letters
Published: October 17, 2025

Depletion of CD8+ CART cells leads to superior anti-tumor efficacy of pure CD4+ CART cells against acute leukemias.

Depletion of CD8+ CART cells leads to superior anti-tumor efficacy of pure CD4+ CART cells against acute leukemias.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 15, 2025

Depletion of CD8+ CAR T-cells leads to superior anti-tumor efficacy of pure CD4+ CAR T-cells against Acute Leukemias.

Depletion of CD8+ CAR T-cells leads to superior anti-tumor efficacy of pure CD4+ CAR T-cells against Acute Leukemias.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 15, 2025

CCCTC-binding factor regulates splicing factor proline and glutamine-rich to promote malignant growth of osteosarcoma.

CCCTC-binding factor regulates splicing factor proline and glutamine-rich to promote malignant growth of osteosarcoma.

Journal: American journal of translational research
Published: December 26, 2024

Subversion of mRNA degradation pathways by EWSR1::FLI1 represents a therapeutic vulnerability in Ewing sarcoma.

Subversion of mRNA degradation pathways by EWSR1::FLI1 represents a therapeutic vulnerability in Ewing sarcoma.

Journal: Nature communications
Published: May 07, 2024

The splicing factor proline and glutamine rich promotes the growth of osteosarcoma via the c-Myc signaling pathway.

The splicing factor proline and glutamine rich promotes the growth of osteosarcoma via the c-Myc signaling pathway.

Journal: American journal of cancer research
Published: March 16, 2023

Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs.

Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs.

Journal: Redox biology
Published: November 08, 2022

miR-1297 inhibits osteosarcoma cell proliferation and growth by targeting CCND2.

miR-1297 inhibits osteosarcoma cell proliferation and growth by targeting CCND2.

Journal: American journal of cancer research
Published: June 06, 2022

Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma.

Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma.

Journal: Frontiers in oncology
Published: February 21, 2022

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.

Journal: Blood
Published: February 07, 2022

Integrated analyses of an RNA binding protein-based signature related to tumor immune microenvironment and candidate drugs in osteosarcoma.

Integrated analyses of an RNA binding protein-based signature related to tumor immune microenvironment and candidate drugs in osteosarcoma.

Journal: American journal of translational research
Published: January 22, 2022
Showing 1-12 of 18

Last Updated: 09/26/2026